Advanced Malignant Solid Neoplasm Resistant to Standard therapy | Metastatic Malignant Solid Neoplasm Resistant to Standard therapy | Standard therapy Unavailable | Measurable lesion | Non-Measurable Lesion
Item
dose escalation population: histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available. lesions may be measurable or non measurable.
boolean
C4329281 (UMLS CUI [1,1])
C0332325 (UMLS CUI [1,2])
C2936643 (UMLS CUI [1,3])
C4287832 (UMLS CUI [2,1])
C0332325 (UMLS CUI [2,2])
C2936643 (UMLS CUI [2,3])
C2936643 (UMLS CUI [3,1])
C0686905 (UMLS CUI [3,2])
C1513041 (UMLS CUI [4])
C1334988 (UMLS CUI [5])
Metastatic Renal Cell Cancer | Systemic therapy Absent Malignant Neoplasm
Item
expansion population 1: patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
boolean
C0278678 (UMLS CUI [1])
C1515119 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0006826 (UMLS CUI [2,3])
Metastatic Renal Cell Cancer | Systemic therapy Malignant Neoplasm | VEGF Inhibitor | Resistant to VEGF Inhibitor | Disease Progression Following Response | In complete remission | Partial response | Stable Disease Duration
Item
expansion population 2: patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent vegf inhibitor and who now have acquired resistance to this treatment. resistance is defined as progression following an initial response (complete or partial), or stable disease for at least 6 months on single agent vegf inhibitor.
boolean
C0278678 (UMLS CUI [1])
C1515119 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C4521299 (UMLS CUI [3])
C0332325 (UMLS CUI [4,1])
C4521299 (UMLS CUI [4,2])
C0242656 (UMLS CUI [5,1])
C0332282 (UMLS CUI [5,2])
C1704632 (UMLS CUI [5,3])
C0677874 (UMLS CUI [6])
C1521726 (UMLS CUI [7])
C0677946 (UMLS CUI [8,1])
C0449238 (UMLS CUI [8,2])
Glioblastoma | Prior Therapy failed | Teleradiotherapy | Temozolomide Chemotherapy | Recurrent disease Radiography | Progressive Disease Radiography
Item
expansion population 3: patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
boolean
C0017636 (UMLS CUI [1])
C1514463 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C0419095 (UMLS CUI [3])
C0076080 (UMLS CUI [4,1])
C0392920 (UMLS CUI [4,2])
C0277556 (UMLS CUI [5,1])
C0034571 (UMLS CUI [5,2])
C1335499 (UMLS CUI [6,1])
C0034571 (UMLS CUI [6,2])
Liver carcinoma Advanced unresectable | Metastatic hepatocellular carcinoma Advanced | Systemic therapy Absent Malignant Neoplasm | Crizotinib plus Sorafenib | Liver function | Liver function Child-Pugh Classification
Item
expansion population 4: patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested. eligibility criteria also include normal hepatic function or child-pugh hepatic function class a.
boolean
C2239176 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1519810 (UMLS CUI [1,3])
C0744869 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1515119 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0006826 (UMLS CUI [3,3])
C2974289 (UMLS CUI [4,1])
C0332287 (UMLS CUI [4,2])
C1516119 (UMLS CUI [4,3])
C0232741 (UMLS CUI [5])
C0232741 (UMLS CUI [6,1])
C2347612 (UMLS CUI [6,2])
Metastatic malignant neoplasm to brain Hemorrhagic | Metastatic malignant neoplasm to brain Symptomatic | Requirement Steroids
Item
patients with hemorrhagic brain metastases or with known symptomatic brain metastases requiring steroids.
boolean
C0220650 (UMLS CUI [1,1])
C0333275 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C1514873 (UMLS CUI [3,1])
C0038317 (UMLS CUI [3,2])
Major surgery
Item
major surgery within 4 weeks of starting study treatment.
boolean
C0679637 (UMLS CUI [1])
Therapeutic radiology procedure
Item
radiation therapy within 2 weeks of starting study treatment.
boolean
C1522449 (UMLS CUI [1])
Uncontrolled hypertension | Blood pressure determination | Therapy Optimal
Item
hypertension that cannot be controlled with medications (>150/90 mmhg despite optimal medical therapy).
boolean
C1868885 (UMLS CUI [1])
C0005824 (UMLS CUI [2])
C0087111 (UMLS CUI [3,1])
C2698651 (UMLS CUI [3,2])
Prior Therapy Glioblastoma | Gliadel wafer | Radiation Stereotactic | Brachytherapy | Exception Recurrent tumor PET scan | Exception Recurrent tumor Perfusion MRI | Intracranial Hemorrhage CTCAE Grades | Therapeutic radiology procedure Glioblastoma
Item
for glioblastoma patients: prior treatment of glioblastoma with gliadel wafers, stereotactic radiation, or brachytherapy unless there is pathological or definitive radiological evidence (pet scan or perfusion mri) of recurrent tumor or unless there is new enhancement outside of the radiation field. history of grade 2 or greater acute intracranial hemorrhage. radiation therapy (rt) for glioblastoma within 3 months unless there is either: a) histopathologic confirmation of recurrent tumor, or b) new enhancement on mri outside of the rt treatment field.concomitant treatment with therapeutic doses of anticoagulants (low dose warfarin (coumadin) up to 2 mg po daily for deep vein thrombosis prophylaxis is allowed).
boolean
C1514463 (UMLS CUI [1,1])
C0017636 (UMLS CUI [1,2])
C1171407 (UMLS CUI [2])
C1522449 (UMLS CUI [3,1])
C0729296 (UMLS CUI [3,2])
C0006098 (UMLS CUI [4])
C1705847 (UMLS CUI [5,1])
C0521158 (UMLS CUI [5,2])
C0032743 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0521158 (UMLS CUI [6,2])
C0879554 (UMLS CUI [6,3])
C0151699 (UMLS CUI [7,1])
C1516728 (UMLS CUI [7,2])
C1522449 (UMLS CUI [8,1])
C0017636 (UMLS CUI [8,2])